论文部分内容阅读
目的:观察苯磺酸左旋氨氯地平对原发性高血压的降压疗效及对颈动脉内膜中层厚度和左室肥厚的影响。方法:160例1～2级原发性高血压患者随机分为苯磺酸左旋氨氯地平治疗组和硝苯地平控释片治疗组,每组各80例。所有患者均随访1年。每例患者前2周测血压2次/周,以后1次/周;治疗前及1年后各做一次颈动脉和心脏超声检查。结果:苯磺酸左旋氨氯地平和硝苯地平控释片均能明显平稳减低血压(P<0.01)和干预颈动脉内膜增厚及左室肥厚(P<0.05),但2组间差异无统计学意义(P>0.05)。结论:苯磺酸左旋氨氯地平除能有效平稳降低高血压患者血压外,还能干预左室肥厚和颈动脉内膜中层厚度。
OBJECTIVE: To observe the antihypertensive effect of levamlodipine besylate on essential hypertension and its effect on carotid intima-media thickness and left ventricular hypertrophy. Methods: One hundred and sixty patients with grade 1 or 2 essential hypertension were randomly divided into L-amlodipine besylate group and nifedipine controlled-release group, 80 cases in each group. All patients were followed up for 1 year. Each patient 2 weeks before the test of blood pressure 2 times / week, after 1 / week; before treatment and 1 year after each carotid and cardiac ultrasound. Results: Both L-amlodipine besylate and nifedipine controlled release tablets could significantly reduce blood pressure (P <0.01) and interfere with carotid intimal thickening and left ventricular hypertrophy (P <0.05), but the differences between the two groups No statistical significance (P> 0.05). Conclusion: Levamlodipine besylate can not only effectively reduce the blood pressure of hypertensive patients, but also interfere the left ventricular hypertrophy and carotid intima-media thickness.